转机，出现在清华大学第一附属医院心脏中心。由张明奎教授领衔的团队，为她实施了一场关键的手术——植入一颗 "人工心脏"，即左心室辅助装置 （LVAD）。这枚精密的机械心脏以坚实、恒久的力量，接过了她心脏最沉重的部分工作，让那颗疲惫不堪的自体心脏，终于获得了喘息与修复的宝贵契 机。 术前： 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ （来源：医学界） 转自：医学界 年轻女性患终末期扩张型心肌病，清华大学第一附属医院团队为她进行了一场关键的救命手术。术后半年，她的生活迎来了巨大的改变。 清华大学第一附属医院 三十五岁，本应是人生中蓬勃有力的年华，但她的世界，却被禁锢于病床的方寸之间。扩张型心肌病终末期，如同一块沉重的巨石，压垮了她心脏最后的 引擎。每一次呼吸都沾染着衰竭的重量，每一次心跳都显得力不从心。严重的活动受限将她牢牢锁在病榻之上，连起身、行走都成了遥不可及的奢望。窗 外的四季更迭、近在咫尺的家常谈笑，都仿佛隔着一层厚厚的毛玻璃，模糊而遥远。她的生命质量，被心衰这无形的敌人一点点蚕食殆尽，在漫长的等待 中，微弱地明灭着。 在医学领域，终末期心力衰竭常被称为 "心脏病的绝症"。传统 ...

Core Insights - Heart failure (HF) is increasingly recognized as a critical area in cardiovascular medicine, with numerous companies making advancements in treatment technologies [1] - The prevalence of heart failure in developed countries is 1%-2%, while in China, it has reached 1.3% among individuals over 35, totaling approximately 13.7 million patients [1] - Current first-line medications only alleviate symptoms without halting disease progression, highlighting the urgent need for innovative treatments [1] Financing Events - Recent financing activities in the heart failure sector include companies like Alleviant Medical raising $90 million, and V-Wave being acquired for $600 million by Johnson & Johnson [2] - A total of over $1 billion has been raised across various companies in the heart failure treatment space, indicating strong investor interest [2] Innovation Directions - The innovation in heart failure treatment can be categorized into four main directions: reducing cardiac load, improving cardiac efficiency, promoting cardiac repair and regeneration, and preventing fluctuations in cardiac load [6][7] - Multiple innovative products are being developed to address different stages of heart failure, including left ventricular assist devices (LVADs) which have seen rapid adoption in recent years [6] Breakthrough Technologies - The FDA's "Breakthrough Devices" designation has been granted to over ten products in the heart failure space, reflecting the clinical demand for innovative therapies [3] - Notable products include Alleviant Medical's atrial shunt device for heart failure with preserved ejection fraction, and various monitoring systems aimed at managing heart failure [4][5] iPSC Cell Therapy - Induced pluripotent stem cell (iPSC) technology is emerging as a promising avenue for heart regeneration, with companies like Alleviant and Heartseed leading the way in clinical trials [8][11] - Alleviant's iPSC-derived cardiac cells have shown safety and potential efficacy in early trials, with plans for further studies and potential commercialization by 2028 [11][13] Atrial Shunt Devices - Atrial shunt devices have gained attention as a viable treatment option, with significant financing activity in this area, although they are still considered a palliative rather than a curative solution [14][16] - The market for atrial shunt devices is evolving, with ongoing clinical trials and a focus on improving patient outcomes through innovative designs [18] Future Directions - The heart failure treatment landscape is shifting from symptomatic management to addressing underlying causes, with a focus on personalized and multimodal approaches [18] - The ultimate goal is to achieve a state where heart failure is preventable, controllable, and potentially curable, driven by advancements in cell and gene therapies, monitoring technologies, and device innovations [18]

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 2025年6月3日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第5号），有 6款产品 进入创新通道。 其中包括， 西安敦博医疗器械有限公司 （简称" 敦博医疗 "）申请的 经导管植入式无导线心脏起搏器 。 敦博医疗创始人 何玉平 曾经表示： "无导线心脏起搏器作为起搏器最新一代技术，具有 更小体积、更便 捷、更安全 的优点，在心脏病的治疗中应用前景广阔。敦博医疗通过 自主研发芯片 ，实现了无导线心脏 起搏器关键技术的突破，不仅赶超了世界最高水平，且又向前多跨了一小步。在技术层面，进一步缩小了 起搏器的体积，大幅度降低了起搏器静态功率，并延长了起搏器的使用寿命，从而使无导线心脏起搏器在 临床中的应用变得更便捷和安全。" # 关于心脏再同步治疗（CRT） 心力衰竭 是一种全球性健康问题，影响着数以千万计的人群。 它是由于 各类心脏疾病导致心脏泵血能力 下降，不能 ...